{
    "nct_id": "NCT04609592",
    "official_title": "Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery",
    "inclusion_criteria": "1. Metastatic gastroenteropancreatic NET with lymph nodes or liver metastases only.\n2. WHO Grade 1 or 2, Ki 67 ≤ 20% (to be confirmed at Stanford)\n3. Must be a candidate for cytoreductive surgery with the goal of R1 resection as determined by a multidisciplinary tumor board discussion\n4. Measurable disease as determined by RECIST v1.1\n5. Confirmed presence of somatostatin receptors on all target lesions as determined by 68Ga DOTA TATE PET scan\n6. Patients ≥ 18 years of age.\n7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1\n8. Appropriate hematologic, liver and kidney function\n9. Patients on octreotide long-acting release (LAR) at a fixed dose of 20 mg or 30 mg at 3 to 4 weeks intervals for at least 12 weeks prior to enrollment in the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior 177Lu Dotatate treatment\n2. Any surgery or radiofrequency ablation within 12 weeks prior to enrollment in the study; or prior radioembolization; chemoembolization; or external beam radiation therapy (EBRT) to > 25% of bone marrow, at any time\n3. Any chemotherapy or targeted therapy (including everolimus and sunitinib) within 4 weeks prior to enrollment in the study\n4. Known brain metastases\n5. Known bone or peritoneal metastases",
    "miscellaneous_criteria": ""
}